Zimmer Biomet Holdings, Inc. (ZBH) Financial Statements
Historical financial data — 39 statements covering FY2016–FY2025
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 a...
Zimmer Biomet Holdings, Inc.'s revenue increased 7.2% year over year, from $7.68B to $8.23B.
Net income decreased 22.0% over the same period, from $903.8M to $705.1M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 7% in total.
Total debt increased by 29.8% to $6.93B.
The debt-to-equity ratio stands at 0.55, indicating a moderate leverage profile.
Operating cash flow grew 13.2% to $1.70B.
Zimmer Biomet Holdings, Inc. maintains a moderate net profit margin of 8.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $3.70B+102.1% | $442.1M | $2.67B | $656.9M | $655.6M | $21.29B | $5.19B | $12.37B |
| Q3 FY2023 | $5.45B+47.4% | $604.8M | $3.91B | $923.5M | $993.2M | $21.22B | $5.13B | $12.51B |
| Q2 FY2024 | $3.83B-29.8% | $415.2M | $2.77B | $617.2M | $597.4M | $21.52B | $3.96B | $12.74B |
| Q3 FY2024 | $5.66B+47.6% | $664.3M | $4.05B | $896.7M | $993.1M | $21.72B | $4.74B | $12.37B |
| Q1 FY2025 | $1.91B-66.2% | $182.0M | $1.36B | $292.3M | $382.8M | $22.18B | $6.58B | $12.40B |
| Q2 FY2025 | $3.99B+108.8% | $334.9M | $2.84B | $592.3M | $761.0M | $22.87B | $6.75B | $12.53B |
| Q3 FY2025 | $5.99B+50.2% | $565.8M | $4.29B | $943.6M | $1.18B | $23.49B | $7.51B | $12.76B |
| Q1 FY2026 | $2.09B-65.2% | $238.1M | $1.51B | $373.2M | $359.4M | $22.72B | $6.30B | $12.67B |
Balance Sheet Summary (Latest Period)
Total Assets
$23.09B
Total Liabilities
$10.39B
Total Equity
$12.70B
Cash & Equivalents
$591.9M
Total Debt
$6.93B
Current Assets
$5.12B
Current Liabilities
$2.58B
Retained Earnings
$11.61B